Literature DB >> 21873545

Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome.

Madhu S Kumar1, Anupama Narla, Atsushi Nonami, Ann Mullally, Nadya Dimitrova, Brian Ball, J Randall McAuley, Luke Poveromo, Jeffrey L Kutok, Naomi Galili, Azra Raza, Eyal Attar, D Gary Gilliland, Tyler Jacks, Benjamin L Ebert.   

Abstract

Large chromosomal deletions are among the most common molecular abnormalities in cancer, yet the identification of relevant genes has proven difficult. The 5q- syndrome, a subtype of myelodysplastic syndrome (MDS), is a chromosomal deletion syndrome characterized by anemia and thrombocytosis. Although we have previously shown that hemizygous loss of RPS14 recapitulates the failed erythroid differentiation seen in 5q- syndrome, it does not affect thrombocytosis. Here we show that a microRNA located in the common deletion region of 5q- syndrome, miR-145, affects megakaryocyte and erythroid differentiation. We find that miR-145 functions through repression of Fli-1, a megakaryocyte and erythroid regulatory transcription factor. Patients with del(5q) MDS have decreased expression of miR-145 and increased expression of Fli-1. Overexpression of miR-145 or inhibition of Fli-1 decreases the production of megakaryocytic cells relative to erythroid cells, whereas inhibition of miR-145 or overexpression of Fli-1 has a reciprocal effect. Moreover, combined loss of miR-145 and RPS14 cooperates to alter erythroid-megakaryocytic differentiation in a manner similar to the 5q- syndrome. Taken together, these findings demonstrate that coordinate deletion of a miRNA and a protein-coding gene contributes to the phenotype of a human malignancy, the 5q- syndrome.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21873545      PMCID: PMC3208282          DOI: 10.1182/blood-2010-12-324715

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

1.  MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells.

Authors:  Margaret S Ebert; Joel R Neilson; Phillip A Sharp
Journal:  Nat Methods       Date:  2007-08-12       Impact factor: 28.547

2.  Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs.

Authors:  Lee P Lim; Nelson C Lau; Philip Garrett-Engele; Andrew Grimson; Janell M Schelter; John Castle; David P Bartel; Peter S Linsley; Jason M Johnson
Journal:  Nature       Date:  2005-01-30       Impact factor: 49.962

3.  MicroRNA expression profiles classify human cancers.

Authors:  Jun Lu; Gad Getz; Eric A Miska; Ezequiel Alvarez-Saavedra; Justin Lamb; David Peck; Alejandro Sweet-Cordero; Benjamin L Ebert; Raymond H Mak; Adolfo A Ferrando; James R Downing; Tyler Jacks; H Robert Horvitz; Todd R Golub
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

4.  EWS/FLI-1 induces rapid onset of myeloid/erythroid leukemia in mice.

Authors:  Enrique C Torchia; Kelli Boyd; Jerold E Rehg; Chunxu Qu; Suzanne J Baker
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

5.  Mammalian microRNAs predominantly act to decrease target mRNA levels.

Authors:  Huili Guo; Nicholas T Ingolia; Jonathan S Weissman; David P Bartel
Journal:  Nature       Date:  2010-08-12       Impact factor: 49.962

6.  Reduced accumulation of specific microRNAs in colorectal neoplasia.

Authors:  Michael Z Michael; Susan M O' Connor; Nicholas G van Holst Pellekaan; Graeme P Young; Robert J James
Journal:  Mol Cancer Res       Date:  2003-10       Impact factor: 5.852

7.  FLI1 monoallelic expression combined with its hemizygous loss underlies Paris-Trousseau/Jacobsen thrombopenia.

Authors:  Hana Raslova; Emiko Komura; Jean Pierre Le Couédic; Frederic Larbret; Najet Debili; Jean Feunteun; Olivier Danos; Olivier Albagli; William Vainchenker; Rémi Favier
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

Review 8.  Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer.

Authors:  B L Ebert
Journal:  Leukemia       Date:  2009-03-26       Impact factor: 11.528

9.  Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype.

Authors:  Daniel T Starczynowski; Florian Kuchenbauer; Bob Argiropoulos; Sandy Sung; Ryan Morin; Andrew Muranyi; Martin Hirst; Donna Hogge; Marco Marra; Richard A Wells; Rena Buckstein; Wan Lam; R Keith Humphries; Aly Karsan
Journal:  Nat Med       Date:  2009-11-08       Impact factor: 53.440

10.  Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth.

Authors:  Xiaohong Wang; Shuang Tang; Shu-Yun Le; Robert Lu; Janet S Rader; Craig Meyers; Zhi-Ming Zheng
Journal:  PLoS One       Date:  2008-07-02       Impact factor: 3.240

View more
  34 in total

Review 1.  Long non-coding RNAs and cancer: a new frontier of translational research?

Authors:  R Spizzo; M I Almeida; A Colombatti; G A Calin
Journal:  Oncogene       Date:  2012-01-23       Impact factor: 9.867

Review 2.  Molecular dissection of the 5q deletion in myelodysplastic syndrome.

Authors:  Benjamin L Ebert
Journal:  Semin Oncol       Date:  2011-10       Impact factor: 4.929

Review 3.  MicroRNAs in myeloproliferative neoplasms.

Authors:  Huichun Zhan; Christopher Cardozo; Azra Raza
Journal:  Br J Haematol       Date:  2013-02-25       Impact factor: 6.998

Review 4.  Molecular pathophysiology of myelodysplastic syndromes.

Authors:  R Coleman Lindsley; Benjamin L Ebert
Journal:  Annu Rev Pathol       Date:  2012-08-28       Impact factor: 23.472

Review 5.  The novel mechanism of lenalidomide activity.

Authors:  Emma C Fink; Benjamin L Ebert
Journal:  Blood       Date:  2015-10-05       Impact factor: 22.113

Review 6.  MicroRNAs in erythroid and megakaryocytic differentiation and megakaryocyte-erythroid progenitor lineage commitment.

Authors:  L Zhang; V G Sankaran; H F Lodish
Journal:  Leukemia       Date:  2012-05-23       Impact factor: 11.528

Review 7.  Current therapy of myelodysplastic syndromes.

Authors:  Amer M Zeidan; Yuliya Linhares; Steven D Gore
Journal:  Blood Rev       Date:  2013-07-27       Impact factor: 8.250

Review 8.  Genetic deletions in AML and MDS.

Authors:  Benjamin L Ebert
Journal:  Best Pract Res Clin Haematol       Date:  2010-11-04       Impact factor: 3.020

9.  α-1,6-Fucosyltransferase (FUT8) inhibits hemoglobin production during differentiation of murine and K562 human erythroleukemia cells.

Authors:  Hitoshi Sasaki; Takanori Toda; Toru Furukawa; Yuki Mawatari; Rika Takaesu; Masashi Shimizu; Ryohei Wada; Dai Kato; Takahiko Utsugi; Masaya Ohtsu; Yasufumi Murakami
Journal:  J Biol Chem       Date:  2013-04-22       Impact factor: 5.157

10.  Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34(+) cells from patients with del(5q) myelodysplastic syndrome.

Authors:  Christopher P Venner; Joanna Wegrzyn Woltosz; Thomas J Nevill; H Joachim Deeg; Gisela Caceres; Uwe Platzbecker; Bart L Scott; Lubomir Sokol; Sandy Sung; Alan F List; Aly Karsan
Journal:  Haematologica       Date:  2012-08-28       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.